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• The effect of screening on the risk of cervical cancer diminishes by decreasing age.
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Available online 21 September 2017Objective. Effectiveness of organized cervical cancer screening has been shown in several studies. However,
screening among women aged b25 years has been suggested to have little or no impact on the risk of cervical
cancer. Also the signiﬁcance of opportunistic testing in preventing cervical cancer is unclear. The aim of this
study was to clarify the effect of opportunistic testing and organized screening on the risk of cervical cancer
among young Finnish women.
Methods. In the Finnish Cancer Registry there were 284 cervical cancer cases diagnosed and tested below the
age of 40 in 2004–2009. Screening histories and data on opportunistic testing for these women and their 1698
age-matched controls were derived from databases of the Mass Screening Registry and The National Institute
for Health and Welfare from 1997 onward. OR's and 95% CI's for the association of cervical cancer diagnosis
and participation in organized screening and opportunistic testing were estimated using unconditional logistic
regression. Results were corrected for self-selection bias and attendance rate.
Results. Among women aged under 25, OR of cervical cancer for any Pap test taken 0.5–5.5 years before diag-
nosis was 1.25 (95% CI 0.46–3.43). Attending only organized screening at age 25–39 resulted in OR 0.52
(0.36–0.77), attending only opportunistic testing in OR 0.86 (0.60–1.25) and attending both in OR 0.48
(0.29–0.79).
Conclusion.Opportunistic testing showed no clear additional beneﬁt on preventing cervical cancer. The study
also supports ﬁndings on a smaller effect of screening in younger age groups.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Outcome1. Introduction
Effectiveness of organized cervical cancer screening has been shown
in several studies [1] [2], [3], but it may be dependent on age. Screening
under 30 years old women has been generally shown to have only littlenioninkatu 22, 00130 Helsinki,
en).
. This is an open access article underimpact on the risk of cervical cancer whereas a clear risk reduction has
been observed in women aged 40 years or over [4–9].
A well-organized screening program is considered to bemore effec-
tive in cancer prevention than opportunistic testing. Further, it results in
lower costs and less harm [10]. [2], [11],In well-organized population-
based screening, all women are followed from the invitation and test
to the potential treatment, and all data of steps are registered. These
data are essential formonitoring and evaluation of the quality and effec-
tiveness of screening. In opportunistic testing, these beneﬁts are often
lost due to incomplete follow-up and lack of registration. Also thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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followed.
A human papilloma virus (HPV) infection is a necessary factor in the
development of precancerous epithelial lesions and further cervical can-
cer [12–14]. Both HPV infections and mild cell atypia are known to be
very prevalent but also transient at young age [15–17]. Pap testing
therefore detects a signiﬁcant number of mild abnormalities and even
precancerous lesions which are likely to be regressive [18]. Excessive
testing at young age thus causes not only more unnecessary testing
and related psychological stress but also overtreatment of pre-
cancerous lesionswhich increases the risk for treatment related compli-
cations in reproductive health [2]. In Finland extensive opportunistic
testing practice is particularly common in young women with low risk
of cervical cancer [19,20].
The aim of the study is to evaluate age-speciﬁc effects of Pap testing
among women aged b40 years using registry-based case-control data.
We also assess differences in the preventive effects of opportunistic
and organized testing against cervical cancer.
2. Material and methods
The organized screening program for cervical cancer in Finland was
initiated in 1963. Municipalities are responsible for organizing the
screening and delivering the results to the nationalMass Screening Reg-
istry. All women aged 30–60 years are invited to screeningwith person-
al letter every ﬁve years. Somemunicipalities have extended invitations
to 25 and/or 65-year olds. Opportunistic Pap testing has emerged later,
after the onset of the organized screening program, but is currently
extensive.
All women aged 13–99 years diagnosed with cervical cancer in
2000–2009 were identiﬁed as cases from the Finnish Cancer Registry
and their age-matched controlswere retrieved from the Population reg-
istry [8]. Screening histories prior to cases' diagnoses for all invited cases
and controls were obtained from 1991 onwards from the Mass Screen-
ing Registry for organized screening. These data were created in 2012Fig. 1. Accumulation ofand included 1546 cases and 9276 controls [8]. For the current study,
we linked these data with available data on opportunistic testing prior
to cases' diagnosis from the research database collected andmaintained
by The National Institute for Health and Welfare (THL). The THL re-
search database includes data from the Social Insurance Institution of
Finland (1997–2008) with Pap smears reimbursed in the private sector
covering the whole country. Other data sources of the THL database are
regional: data from the Finnish Student Health Service (2000–2008) in-
cludes Pap smears taken in the student health care covering the univer-
sity towns, and data from the Southern Finland, i.e. from Turku region
(2002–2009) and the capital region (2000–2009), include Pap smears
taken in the public primary health care services. Diagnostic Pap tests,
i.e. tests taken within the six-month period before cases' diagnoses
were excluded. All data were linked with unique personal identiﬁer as
a key.
We restricted the data to cases aged b40 years at the time of a pre-
ventive Pap test and their respective controls. The preventive Pap test
was deﬁned to take place at least sixmonths before the diagnosis of cer-
vical cancer. Only women with the latest invitation for organized
screening in 1997 or later were included in the study due to lack of op-
portunistic data before that year. To ensure adequate screening history
only cases diagnosed from 2004 onwards and their respective controls
were included. Overall, our study included 284 cases and 1698 controls,
altogether 1982women (Fig. 1). Women under the age of 30 composed
approximately 28% of the whole study population. There were only 23
cases tested under the age of 25 (Table 1). Among them, two cases
were diagnosed under the age of 15 and rest of them over the age of
20. Subgroup analyses were performed by morphology (squamous cell
carcinoma and adenocarcinoma) and stage (carcinomas with Figo
stage at least IB).
We estimated the association between the risk of cervical cancer and
protective Pap testing using unconditional logistic regression adjusted
for year of birth. Pap smears taken during the samemonth were count-
ed only once since subsequent tests were regarded as retests due to a
failure in the previous test. We examined a time period of 10 yearscases and controls.
Table 1
Age distribution and the availability of organized and opportunistic data for cases and con-
trols by age at testing.
Age at testing Cases N (%) Controls N (%) Total N (%)
b25 23 (8.1) 147 (8.7) 170 (8.6)
25–29 61 (21.5) 330 (19.4) 391 (19.7)
30–34 91 (32.0) 591 (34.8) 682 (34.4)
35–39 109 (38.4) 630 (34.8) 739 (37.3)
All/b40 284 (100.0) 1698 (100.0) 1982 (100.0)
No test/NA 0.5–10.5 years before diagnosis1
b25 15 (65.2) 93 (63.3) 108 (63.5)
25–29 28 (45.9) 136 (41.2) 164 (41.9)
30–34 32 (35.1) 144 (24.3) 176 (25.8)
35–39 36 (33.0) 105 (16.7) 148 (20.0)
All/b40 111 (39.0) 478 (28.2) 589 (29.7)
Invited to organized screening 0.5–10.5 years
before diagnosisa
Cases N
(%)
Controls N
(%)
Total N
(%)
b25 0 (0.0) 6 (4.1) 6 (3.5)
25–29 22
(36.0)
99 (30.0) 121
(30.9)
30–34 73
(80.2)
503 (85.1) 576
(84.5)
35–39 94
(86.2)
584 (92.7) 678
(91.7)
All/b40 189
(66.5)
1192
(70.2)
1381
(69.7)
Participated to organized screening 0.5–10.5
years before diagnosisa
Cases N
(%)
Controls
N (%)
Total N
(%)
b25 0 (0.0) 1 (0.7) 1 (0.0)
25–29 6 (9.8) 40 (12.4) 46
(12.0)
30–34 40
(44.0)
316
(55.2)
355
(53.7)
35–39 56
(51.4)
442
(69.7)
496
(67.0)
All/b40 102
(35.9)
799
(47.5)
898
(45.9)
Participated to opportunistic testing 0.5–10.5
years before diagnosisa
Cases N
(%)
Controls
N (%)
Total N
(%)
b25 8 (34.8) 54 (36.7) 62
(36.5)
25–29 29
(47.5)
174
(52.7)
203
(51.9)
30–34 37
(40.7)
282
(47.7)
319
(46.8)
35–39 40
(36.7)
270
(42.9)
310
(41.9)
All/b40 114
(40.1)
780
(45.9)
894
(45.1)
a Percentages are presented as proportions of the age group concerned.
Table 2
Stage and morphology distributions for all cases.
Figo stage Cases N (%)
IA 122 (43.0)
IB-IIA 102 (35.9)
IIB+ 32 (11.3)
Unknown 28 (9.9)
Total 284 (100.0)
Morphology Cases N (%)
Squamous cell carcinoma 191 (67.3)
Adenocarcinoma 69 (24.3)
Others 24 (8.5)
Total 284 (100.0)
Morphology stage Ia excluded
Squamous cell carcinoma 91 (32.0)
Adenocarcinoma 50 (17.6)
Others 21 (7.3)
Total 162 (57.0)
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ther divided in two 5-year periods (0.5–5.5 and 5.5–10.5 years). In the
primary analyses any Pap test taken (yes/no) during the ﬁrst 5-year pe-
riod before the cases diagnosis was used as a primary exposure. To as-
sess differences in the preventive effects of opportunistic and
organized testing in that 5-year period, Pap tests were categorized
into four categories (no tests, only an organized test, only an opportu-
nistic test, both organized and opportunistic test) which were used as
a secondary exposure. The latter analysis included only women who
could have received an invitation to organized screening, i.e. those
aged at least 25 years at testing. In the secondary analyses, Pap tests
taken during a 10-year period before the cases' diagnosis were used as
an exposure. The reference group (baseline) in all analyses was
women with no test or information not available within the 0.5–10.5
time period before cases' diagnosis.
Results were corrected for self-selection by applying a formula from
Duffy et al. [21] The correction factor 1.19 was obtained from Lönnberg
et al. [8] and attendance rate 75% was estimated from our data.2.1. Sensitivity analyses
Comprehensive data on opportunistic tests was available only for
the southern parts of the country. We therefore evaluated whether
the incompleteness of opportunistic data affected on results and conclu-
sions. For that, womenwere categorized into two groups based on their
residential municipality at the latest invitation to organized screening
prior to cancer diagnosis (women from the southern parts of the coun-
try; women from other parts of the country). The completeness indica-
tor based on this regional categorization was included in the models
with its interaction with primary and secondary exposures. Analyses
were also conducted by restricting the data only for the southern parts
of Finland and data was assessed also by individual years during the
study period.
The true correction factor for self-selection is not known. We there-
fore explored also the effect of other plausible correction factors, 1.1 and
1.3, on Results.
Age distributions among women participating in organized screen-
ing and opportunistic testing vary from each other and the preventive
impact of Pap test on the risk of cervical cancer seems to be dependent
on age. For that reason we also evaluated whether age categorized into
5-year groups interacts with the effects of the mode of testing (second-
ary exposure).
In sensitivity analyses exact logistic regression was used instead of
unconditional logistic regression if the number of women in a certain
group was lower than ﬁve.
Stata version 14.0 was used in all the analyses.3. Results
In the time period of 0.5–10.5 years before the cases' diagnosis 128
(45%) of the cases and 852 (50%) of the controls had had one or two
Pap tests taken (further results not presented). 45 (16%) of the cases
and 368 (22%) of the controls had had three ormore Pap tests. The base-
line, women with no test or information not available within the 0.5–
10.5 time period before cases' diagnosis, consisted of 111 (39%) cases
and 478 (28%) controls (Table 1). 67% of the cases and 70% of the con-
trols had received an invitation for organized screening and data on op-
portunistic tests was available for 40% of the cases and 46% of the
controls. Amongwomen aged below 30 years, the coverage of the orga-
nized invitations was poor. In older age groups the coverage was ap-
proximately 80–90%. The coverage of opportunistic testing was
highest among women aged 25–29 years (52%). A clear majority of
the cancer cases were stage IA (43%) or IB-IIA (36%) whereas advanced
stage IIB+ was rare (11%) (Table 2). Regarding morphology, squamous
Table 3
Associations between organized and opportunistic testing 0.5–5.5 years before diagnosis and the risk for cervical cancer by ﬁve-year age group.
Age at testing Cases tested Y/Na Controls tested Y/Na Crude OR (95% CI) Corrected OR (95% CI)b
b25 8/15 54/93 0.98 (0.36–2.70) 1.25 (0.46–3.43)
25–29 30/28 175/136 0.82 (0.47–1.45) 1.04 (0.60–1.84)
30–34 51/32 414/144 0.56 (0.35–0.90) 0.71 (0.44–1.14)
35–39 54/36 454/105 0.34 (0.21–0.54) 0.43 (0.27–0.69)
b30 38/43 229/229 0.68 (0.48–0.97) 1.08 (0.66–1.78)
b40 143/111 1097/478 0.54 (0.40–0.71) 0.70 (0.51–0.90)
Stage IA excluded
b25 2/9 30/46 0.33 (0.03–2.05)c 0.42 (0.04–2.60)
25–29 14/12 78/61 0.91 (0.39–2.12) 1.16 (0.50–2.69)
30–34 25/20 221/75 0.45 (0.23–0.86) 0.57 (0.29–1.09)
35–39 38/25 311/75 0.32 (0.18–0.56) 0.41 (0.23–0.71)
b30 16/21 108/107 0.73 (0.35–1.52) 0.93 (0.44–1.93)
b40 79/66 640/250 0.43 (0.30–0.63) 0.55 (0.38–0.80)
By morphology
SCCd
b25 4/9 30/52 0.88 (0.17–3.75)c 1.11 (0.22–4.76)
25–29 19/18 115/96 0.88 (0.43–1.76) 1.12 (0.55–2.23)
30–34 30/26 277/106 0.44 (0.25–0.78) 0.56 (0.32–0.99)
35–39 37/24 315/80 0.39 (0.22–0.69) 0.49 (0.28–0.88)
b30 23/27 145/148 0.86 (0.46–1.59) 1.09 (0.58–2.02)
b40 90/77 737/334 0.51 (0.36–0.72) 0.65 (0.46–0.91)
Stg Ia exc. b40 43/36 365/144 0.46 (0.28–0.75) 0.58 (0.36–0.95)
Adenocarcinoma
b25 3/3 13/21 1.64 (0.18–14.69)c 2.08 (0.23–18.66)
25–29 8/6 43/27 0.67 (0.20–2.32) 0.85 (0.25–2.95)
30–34 16/4 101/30 1.28 (0.39–4.20) 1.62 (0.50–5.34)
35–39 16/7 113/22 0.41 (0.15–1.13) 0.41 (0.52–1.44)
b30 11/9 56/48 0.91 (0.33–2.53) 0.91 (1.16–3.21)
b40 43/20 270/100 0.80 (0.43–1.46) 1.08 (0.55–1.85)
Stg Ia exc. b40 29/16 197/68 0.59 (0.29–1.20) 0.75 (0.37–1.52)
a Number of cases and controls with invitation and exposed to Pap testing yes/no.
b Corrected using self-selection bias factor 1.19 and attendance rate 0.75.
c Estimated using exact logistic regression.
d Squamous cell carcinoma.
Table 4
Association between the mode of testing and the risk of cervical cancer 0.5–5.5-years be-
fore diagnosis in women tested at ages 25–39.
Mode of Pap
testing
Cases no.
%
Controls no.
%
Crude OR
(95% CI)
Corrected OR
(95% CI)a
No test/NAb 96 (45.3) 385 (29.5) 1 1
Only organized 41 (19.3) 383 (29.3) 0.41 (0.28–0.61) 0.52 (0.36–0.77)
Only opportunistic 52 (24.5) 306 (23.4) 0.68 (0.47–0.98) 0.86 (0.60–1.25)
Both 23 (10.8) 233 (17.8) 0.38 (0.23–0.62) 0.48 (0.29–0.79)
Totalc 212 (100) 1307 (100)
a Corrected using self-selection bias factor 1.19 and attendance rate 0.75.
b Not available.
c Restricted to age 25–39 years, 49 cases and 244 controls had a Pap test only in 5.5–
10.5 years before diagnosis and therefore they were excluded in the analysis.
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24%, respectively).
Compared to womenwith no test or information on testing, any Pap
test 0.5–5.5 years before the diagnosis reduced the risk of cervical can-
cer at age b40 years by 30% (OR corrected for self-selection of 0.70
with 95% CI 0.51–0.90, Table 3). The preventive effect increased by age
being statistically signiﬁcant only at ages 35–39 years (OR 0.43 with
95% CI 0.27–0.69). The subgroup-analyses by morphology included
167 cases with SCC and 63 with adenocarcinoma (Table 3). The OR of
any Pap test for SCC was 0.65 (95% CI 0.46–0.91). For adenocarcinoma
there was no impact (OR 1.08, (95% CI 0.55–1.85). Further, a sub-
analysis restricted to cancers with Figo stage at least IB with 145 cases
resulted in OR of 0.55 (95% CI 0.38–0.80). The strengthening preventive
effect of Pap testing by increasing age was seen also in all subgroup-
analyses, though the number of cases was small especially in the youn-
ger age groups.
In the secondary analyses for ages 25–39 years, OR for attending
only organized screening was 0.52 (95% CI 0.36–0.77). The correspond-
ing OR for attending both organized and opportunistic testing was 0.48
(95% CI 0.29–0.79) (Table 4). There was no difference in the risk of cer-
vical cancer between women attending both organized screening and
opportunistic testing and women attending only organized screening
(p = 0.77). OR for attending only opportunistic testing was 0.86 (95%
CI 0.60–1.25) (Table 4).
When comparing the preventive effects of Pap testing by the 5-
year time periods, any Pap smear taken in 0.5–5.5 years before the
diagnosis resulted in OR of 0.72 (0.95% CI 0.52–1.00) (Table 5). Addi-
tional Pap smear taken 5.5–10.5 years before the diagnosis didn't in-
crease the effect (p = 0.50). Pap tests taken only 5.5–10.5 years
before the diagnosis didn't protect against cervical cancer (OR 1.26
with 95% CI 0.79–1.98).3.1. Sensitivity analyses
In the sensitivity analyses, the effect of Pap testing for the risk of cer-
vical cancer did not differ substantially between the southern parts of
Finland and the rest of the country. For the southern Finland alone, OR
of any Pap test for the risk of cervical cancer was 0.58 (95% CI 0.30–
1.08) based on 69 cases and 456 controls (Supplementary Table 1).
The analyses, however, emphasized some differences between the im-
pacts of organized screening and opportunistic testing on the risk of cer-
vical cancer. For the southern Finland alone, the effect of having only
had an opportunistic testing remained constant and non-signiﬁcant
(OR 0.84 with 95% CI 0.42–1.69). Attending only organized screening
or both organized screening and opportunistic testing resulted in OR
of 0.30 (95% CI 0.11–0.86) and 0.22 (95% CI 0.09–0.55), respectively;
i.e. these effects were stronger compared to the effects regarding the
whole country (Supplementary Table 2).
Table 5
Associations between the period of testing and the risk of cervical cancer in the study
population.
Time period before diagnosis
0.5–5.5 5.5–10.5 Cases No.
%
Controls No.
%
Crude OR
(95% CI)
Corrected OR
(95% CI)a
No/NAb No/NAb 111 (39.1) 478 (28.2) 1 1
Yes No/NAb 76 (26.8) 555 (32.7) 0.57 (0.41–0.79) 0.72 (0.52–1.00)
No/NAb Yes 30 (10.6) 123 (7.2) 0.99 (0.62–1.56) 1.26 (0.79–1.98)
Yes Yes 67 (23.6) 542 (31.9) 0.50 (0.36–0.71) 0.64 (0.46–0.90)
Total 284 (100) 1698 (100)
a Corrected using self-selection bias factor 1.19 and attendance rate 0.75.
b Not available.
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in the analyses, but also explored the effect of factors 1.1 and 1.3 on our
results.With all these correction factors themain results remained con-
stant. Amongwomen aged under 30 years, OR of any Pap test for the risk
of cervical cancer was 0.86 (95% CI 0.51–1.45) with factor 1.1 and 1.10
(95% CI 0.65–1.83) with factor 1.3, respectively.
Age didn't have an interaction with the mode of testing (p= 0.26).
Therefore the stronger preventive effect of organized screening com-
pared to that of opportunistic testing couldn't be explained by the dif-
fering age distribution.
4. Discussion
According to our results, the effect of screening on the risk of cervical
cancer appears to diminish by decreasing age. Any Pap test reduces the
risk for cervical cancer in a 5-year period before the diagnosis clearly
among women aged 35 to 39 years old, but at younger ages the effect
was small. Under the age of 25 Pap testing appeared to have no impact.
We also found that opportunistic testing on top of attending organized
screening showed no clear additional beneﬁt on preventing cervical
cancer. This reinforces the general understanding that for optimal effec-
tiveness cervical cancer screening can and should be offered within an
organized program [11].
The strength of our study is that also opportunistic testingwas taken
into account in evaluating the effect of screening on the risk of cervical
cancer. Data regarding opportunistic testingwas based on data available
from registries and electronical databases in health care, not on a ques-
tionnaire. Unfortunately due to lack of national register of opportunistic
Pap tests, the availability of opportunistic data was limited and we had
fully covering data only for the southern parts of the country.
Principally the sensitivity analyses indicated that the effect of Pap
testing was not dependent on the completeness of opportunistic data
except regarding the analysis of mode of testing, i.e. when the risk of
cervical cancer was compared between women who had attended
only organized screening, only opportunistic testing or both. Even so
the effect of opportunistic Pap testing remained persistently non-
signiﬁcant while the effect of organized screening actually seemed to
strengthen. When the analysis was restricted only to the southern
parts of Finland, attending any Pap test reduced the risk of cervical can-
cer around 50% also in younger age groups of 25–29 and 30–34 years. It
is worth noting, though, that conﬁdence intervals were wide and the
proportion of cases tested at least once in the ﬁve-year time period
was large (78% of the cases compared to 79% of the controls aged
b30 years, Supplementary Table 1). Nevertheless, due to lack of com-
prehensive opportunistic data the poor effect of opportunistic testing
could be at least partially due to lack of power. The number of cases
was small as cervical cancer is a rare disease among young women.
Regarding organized screening, the data available was comprehen-
sive. In younger age groups women are invited for screening from the
age 25 or 30 years onwards depending on the residential municipality.
The invitational coverage in older age cohorts was almost complete.
Reasons for lacking an invitation in age groups 30–40 years wereinternal immigration, disregard for the national screening age recom-
mendations by the residential municipality, andmissing invitational in-
formation from the residential municipality (i.e. the real status of
invitation was unknown) [8].
Also earlier studies have found similar results compared to ours'.
Sasieni et al. [7] showed that screening for cervical cancer in women
aged 20–24 has little or no impact on rates of invasive cervical cancer
up to age 30. According to Zappa et al. [5] there was a marked increase
in the level of protection for women older than 40 years. Yang et al. [22]
found that unadjusted relative risk estimates appeared to indicate that
Pap tests might be more protective for older than for younger women.
On the other hand rather a strong impact irrespective of agewas report-
ed in a Swedish study [23] where clear effects of screening were found
also at the age of 21 to 29, though results were considered to be inﬂu-
enced at least partly by selection bias [7]. As a response to the critic,
the authors showed that the effect persisted among women aged
27–29 if analysis was restricted to stage IB+ cancers whereas not
among women aged 23–26 [24].
Lack of opportunistic data is a general problem in studies comparing
the impact of an organized screening to opportunistic testing on cervical
cancer. There are few studies of this subject and they are primarily de-
scriptive [2]. Nieminen et al. [10] showed that the substantial decrease
in the incidence of and mortality due to cervical cancer in Finland is
mainly due to the organized screening. Pap smears taken in the orga-
nized screening programhad a larger effect on invasive cervical carcino-
ma (adjusted OR 0.38) than a Pap smear taken outside the program
(adjusted OR 0.82). However, the risk estimates may have been subject
to recall bias as data on personal Pap smear history was collected via a
questionnaire.
Reasons for poorer effect of opportunistic testing could be e.g. lack of
quality assurance and monitoring, related to lack of organization of ser-
vices and central registration. Health care providers may not know
about tests taken by other providers and no provider has a full respon-
sibility of organizing a proper follow-up. In addition to poorer effect,
many cost-effectiveness studies consistently report that organized
screening is more cost-effective than opportunistic testing [2]. In
Finland, costs produced by opportunistic testing were estimated to be
two to three folds higher compared to organized screening [20]. [19],
In many European countries screening for cervical cancer begins at
ages 24–25 years and the recommended screening interval can be
three years instead of ﬁve [4,5]. In other Nordic countries beginning to
screen for cervical cancer earlier than Finland and adhering to shorter
3-year screening interval there is no historical decrease in the trends
of cervical cancer among women aged under 30 years [2,25]. In
Finland, the recommended interval is ﬁve years in all age groups. Al-
though participation in organized screening in younger age groups
from 25 to 35 is alarmingly low (51–61%), when including Pap tests
taken bothwithin and outside the organized program, the 5-year cover-
age of Pap smears is high 85–90% [19]. Furthermore, it has been evalu-
ated that two thirds of women aged 20–24 years, not yet even eligible
for organized screening, are tested outside the organized screening pro-
gram [19]. However, the incidence of cervical cancer has increased
steadily from the 1990′s among 25–39 year old women in Finland de-
spite active Pap testing in these age groups. The ﬁrst peak in the age-
speciﬁc incidence rate is at ages 30–39 years [1]. [26], [25],
The increased incidence of cervical cancer among younger women
seems not to be due to lack of screening. Perhaps most importantly, eti-
ological risks have also increased over time. Sexual behavior has indeed
changed during the last decades and the role of oncogenic sexually
transmittedHPV infectionmight have grown in the development of cer-
vical cancer [2] as the life time number of sexual partners has increased
[27] and the age of onset of sexual life has decreased [27]. Further, to-
bacco smoking, which decreases the clearance of HPV and increases
the risk of cervical cancer [28] [29], [30], increased in the 1980′s
among youngwomen and stayed on that level before starting to slightly
decrease in the 2000′s [31] [32],. Nevertheless we cannot rule out that
606 P. Makkonen et al. / Gynecologic Oncology 147 (2017) 601–606more frequent screening could have some effect on the incidence of cer-
vical cancer also in women younger than 35 years. Active testing might
result in cervical cancers to be diagnosed at an early phase.
Pap testing seems not to have a clear impact on the risk of cervical
cancer at young age, especially considering women aged under 25. In
this age group asymptomatic women should not be tested. HPV infec-
tion is very common among young women and a majority of the pre-
invasive lesions would not progress into invasive cancer even if not di-
agnosed and if left untreated. There aren't any unambiguous means to
distinguish the progressive lesions from the non-progressive ones and
the resulting overdiagnosis may bemore harmful than beneﬁcial by in-
creasing the risk for complications and psychological stress. Instead of
frequent non-organized Pap testing, information and education of the
risk factors for cervical cancer and of the importance of attending the or-
ganized screening program should be emphasized amongwomen. Also,
as vaccines against oncogenic HPVs are now available offering a means
to intervene in the HPV epidemic, advocating for the HPV vaccine pro-
gram should be a priority in adolescent health care.
To conclude, taking into account the high costs of opportunistic test-
ing and related CIN treatments in young women, unnecessary Pap test-
ing in younger age-groups should be avoided. Also practices of health
care professionals resulting in excessive opportunistic testing should
be revised as health care professionals are in a crucial position in the
transition from excessive opportunistic testing to better compliance in
organized screening. HPV vaccines have been demonstrated to reduce
incidence of precancerous lesions, even though their effect on cervical
cancer is not yet available. Though vaccination programs against HPV
infections should be a priority in cervical cancer control in young
women, screening programs will still remain crucial in the preventive
strategy for cervical cancer. Efforts are still needed to deﬁne optimal
starting ages of organized cervical cancer screening programs, and
also by authorities to make the organized program more appealing by
improving its proﬁle and practicalities.
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